Denali secures $500m to develop neurodegenerative disease treatments
Longevity Technology - 28-Feb-2024Investment fuels its blood-brain barrier-crossing tech for better drug delivery
Join the club for FREE to access the whole archive and other member benefits.
Company focused on the discovery and development of therapies for patients with neurodegenerative diseases
Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families. Our scientific approach is based on three core principles: rigorous assessment of genetic targets, engineering brain delivery, and using biomarkers to guide development.
Our team thrives in a work environment that is scientifically driven, impact-focused, supportive, and collaborative. Our ability to have a positive impact on people’s lives is directly related to the trust we have in each other and our ability to unify our diverse backgrounds and experience behind our purpose to defeat degeneration.
Visit website: https://www.denalitherapeutics.com/
Details last updated 26-Feb-2022
Investment fuels its blood-brain barrier-crossing tech for better drug delivery
Approaches include senotherapeutics, stem cells and mitochondria. Eye disease is a common first target.